March 2026 in “Clinical Cosmetic and Investigational Dermatology” Rituximab can cause skin issues, but baricitinib may help improve them.
June 2025 in “Revista Foco” JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
June 2023 in “Dermatology and therapy” Doctors in the Middle East need better treatments and more knowledge about new therapies for hair loss condition Alopecia Areata.
July 2023 in “The Egyptian Journal of Hospital Medicine ” Alopecia areata is a hair loss condition caused by immune factors and can be treated with JAK inhibitors.
July 2024 in “Journal of Investigative Dermatology” ITK inhibitors may effectively treat alopecia areata.
October 2024 in “Clinical Cosmetic and Investigational Dermatology” Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.
September 2023 in “Dermatology and therapy” Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
March 2024 in “Dermatology and therapy” AA patients with comorbid conditions face more severe hair loss and need specific treatments.
5 citations
,
February 2024 in “Clinical Pharmacokinetics” A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
December 2023 in “JEADV Clinical Practice” A woman's hair grew back with baricitinib treatment, but she developed a temporary hairy tongue that was treated with regular tongue brushing.
59 citations
,
September 2021 in “Journal of Allergy and Clinical Immunology” Netherton syndrome has two subtypes with shared immune traits but different allergic and immune responses, suggesting targeted treatments.
6 citations
,
October 2024 in “Journal of Family Medicine and Primary Care” Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.
September 2025 in “Australasian Journal of Dermatology” New medications could improve treatment for severe alopecia areata in Australia.
489 citations
,
November 2021 in “Signal Transduction and Targeted Therapy” The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.
277 citations
,
December 2019 in “Frontiers in Immunology” JAK inhibitors show promise for treating skin disorders like alopecia, eczema, and psoriasis.
August 2025 in “Dermatology and Therapy” JAK inhibitors show promise for treating alopecia areata but have serious side effects.
55 citations
,
October 2015 in “Journal of Investigative Dermatology” Alopecia areata is linked to immune-related genes, suggesting JAK inhibitors as a potential treatment.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
5 citations
,
April 2025 in “Journal of Cosmetic Dermatology” Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
4 citations
,
January 2023 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
2 citations
,
May 2025 in “Archives of Dermatological Research” JAK inhibitors do not increase cancer risk in severe alopecia areata compared to traditional treatments.
April 2026 in “Journal of Inflammation Research” Alopecia areata and atopic dermatitis share immune system issues, and treatments like JAK inhibitors can help both.
June 2025 in “Journal of Education Health and Sport” Oral JAK inhibitors show promise for treating alopecia areata but have challenges like relapse and side effects.
May 2024 in “Archives of dermatological research” Enz_MoriL from mulberry leaves helps hair growth by affecting specific cell pathways.
August 2023 in “JAAD international” Pediatric dermatologists have varied preferences for treating alopecia areata in children, with no standard FDA-approved treatments and some using JAK inhibitors despite risks.
July 2023 in “IntechOpen eBooks” New treatments for alopecia areata show promise, but more research is needed to confirm their effectiveness.
May 2023 in “Journal of managed care & specialty pharmacy” Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.
July 2025 in “Cell & Bioscience” Specific immune cells and pathways contribute to hair follicle inflammation and hair loss, suggesting potential treatments for lichen planopilaris.
8 citations
,
July 2024 in “European journal of medical research” Alopecia areata after COVID-19 vaccination is rare but important to recognize for timely treatment.
January 2026 in “Skin Health and Disease” Irish dermatologists use JAK inhibitors for alopecia areata but want standardized treatment guidelines.